The problem of generalizing the mathematical model of pharmacokinetics-pharmacodynamics for anti-PD-1 drugs

Kireev B.V., Nikitich A.A.

Sechenov First Moscow State Medical University 8(499)248-53-83 Сall-center of University: 8 (495) 609-14-00;

Immunotherapy with aPD-1/a-PD-L1 checkpoint inhibitors is effective for tumors resistant to other treatments. Blocking the interaction of PD-1 with PD-L1 avoids immunosuppressive responses in T cells. The use of generalized mathematical models is a good tool for selecting the minimum effective dose in the early stages of clinical trials.

The mathematical model is a system of ordinary differential equations. The model includes 5 compartments: peripheral, central, vessels, endosomal space, interstitial space. The aPD-1 antibody binds to its ligand PD-L1 in the central compartment and in the interstitial space of the tumor. For the summarized drug (Nivolumab), the binding parameters were taken from the literature [1]. The other parameters were determined using the concentration profile of Nivolumab.

The mathematical model of Lindauer et al [2] for aPD-1 antibody (Pembrolizumab) was chosen as a generalization model. The model describes experimental data of aPD-1 (Nivolumab) occupied receptors in plasma.

The model was used to analyze the dependence of Kd on RO. Even on a small amount of data, the curve can be characterized as a linear dependence.

The mathematical model of Lindauer et al [2] aPD-1 antibody is summarized. This model describes the RO in plasma of Nivolumab and can be applied to other aPD-1 antibodies. (3)


1. Brown M. E. et al. Assessing the binding properties of the anti-PD-1 antibody landscape using label-free biosensors //PLoS One. Vol. 15. No. 3. 2020. Pp. e0229206.

2. Lindauer A. et al. Translational pharmacokinetic/pharmacodynamic modeling of tumor growth inhibition supports dose‐range selection of the anti–PD‐1 antibody pembrolizumab //CPT: pharmacometrics & systems pharmacology. Vol. 6. No. 1. 2017. Pp. 11-20.


© 2004 Designed by Lyceum of Informational Technologies №1533